Fig. 1From: Upfront dexrazoxane for the reduction of anthracycline-induced cardiotoxicity in adults with preexisting cardiomyopathy and cancer: a consecutive case seriesClinical protocol for patients with existing cardiomyopathy requiring anthracycline therapyBack to article page